Mortality in an Urban Cohort of HIV-Infected and At-Risk Drug Users in the Era of Highly Active Antiretroviral Therapy
Open Access
- 15 September 2005
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 41 (6) , 864-872
- https://doi.org/10.1086/432883
Abstract
Background. Mortality trends among drug users in the era of highly active antiretroviral therapy (HAART) remain unclear. Methods. We examined mortality rates, causes of death, and predictors of mortality in 398 human immunodeficiency virus (HIV)—infected and 656 at-risk drug users for the period of 1996–2001. National death index reports were used to confirm deaths, and causes of death were derived from medical records. Cox proportional hazards models were used to determine factors associated with mortality. Results. During 1996–2001, mortality rates in HIV-infected and HIV-uninfected participants were 7.3 and 1.5 deaths per 100 person-years, respectively (P < .001). The mean age at the time of death was 43.6 years for HIV-infected subjects and 47.7 years in HIV-uninfected subjects (P < .001). For 398 HIV-infected participants who were observed for 1443 person-years, death rates decreased from 11.4 to 5.4 deaths per 100 person-years over the 6-year period (P = .04). Among all participants, causes of death were as follows: HIV/AIDS, 27% of subjects; substance abuse, 31%; bacterial infection, 25%; other medical illness, 14%; and violence, 3%. Persons who initiated HAART at a CD4+ lymphocyte count of 201–350 cells/mm3 experienced improved survival, compared with those who initiated it at a CD4+ lymphocyte count of ⩽200 cells/mm3 (P = .01). In a multivariate Cox model of HIV-infected subjects, factors independently associated with mortality included receipt of HAART (adjusted hazard ratio [HRadj], 0.44; 95% confidence interval [CI], 0.28–0.68) and CD4+ lymphocyte count of ⩽200 cells/mm3 (HRadj, 4.23; 95% CI, 2.24–7.60). Use of methadone or illicit drugs did not predict mortality. Conclusions. To further reduce mortality among drug users, interventions aimed at improving HAART use are warranted. Preventive health and timely management of treatable conditions, such as bacterial infections, also needs emphasis.Keywords
This publication has 26 references indexed in Scilit:
- Racial and Gender Disparities in Receipt of Highly Active Antiretroviral Therapy Persist in a Multistate Sample of HIV Patients in 2001JAIDS Journal of Acquired Immune Deficiency Syndromes, 2005
- Mortality rates and causes of death in a cohort of HIV-infected and uninfected women, 1993–1999Journal of Urban Health, 2003
- Limited effect of highly active antiretroviral therapy among HIV-positive injecting drug users on the population levelEuropean Journal of Public Health, 2003
- Time to initiating highly active antiretroviral therapy among HIV-infected injection drug usersAIDS, 2001
- A Comparison of Exposure Groups in the EuroSIDA Study: Starting Highly Active Antiretroviral Therapy (HAART), Response to HAART, and SurvivalJAIDS Journal of Acquired Immune Deficiency Syndromes, 1999
- Natural history of HIV infection in the_era of combination antiretroviral therapyAIDS, 1999
- Variations in the Care of HIV-Infected Adults in the United StatesPublished by American Medical Association (AMA) ,1999
- Self-reported Antiretroviral Therapy in Injection Drug UsersJAMA, 1998
- Barriers to Use of Free Antiretroviral Therapy in Injection Drug UsersJAMA, 1998
- Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1998